Anthony Schwartz

Anthony Schwartz Email and Phone Number

Chief Operating Officer @ Miletus Biotechnology
Saint Petersburg, FL, US
Anthony Schwartz's Location
St Petersburg, Florida, United States, United States
Anthony Schwartz's Contact Details

Anthony Schwartz work email

Anthony Schwartz personal email

About Anthony Schwartz

Highly ambitious, motivated and driven business and science professional with over 20 years of experience in starting, managing and consulting with small to mid-stage biotechnology companies. Significant expertise in preclinical and clinical trials to support human and veterinary product approval. Co-founded several profitable companies, achieved FDA approval, the patent holder on multiple cancer drugs, published in prestigious journals and presented at conferences around the world as a recognized key opinion leader.

Anthony Schwartz's Current Company Details
Miletus Biotechnology

Miletus Biotechnology

View
Chief Operating Officer
Saint Petersburg, FL, US
Anthony Schwartz Work Experience Details
  • Miletus Biotechnology
    Chief Operating Officer
    Miletus Biotechnology
    Saint Petersburg, Fl, Us
    View
  • Primera Therapeutics
    Head Of Business Development
    Primera Therapeutics Jan 2022 - Present
    Rockville, Maryland, Us
    Primera Therapeutics is focused on addressing the root cause of mitochondrial diseases by developing a first-in-class gene editing platform to target inherited mutant mitochondrial DNA. Primera’s first approach uses a fully customizable TALE-based system to specifically target a stretch of DNA and a molecule that can correct the mutant DNA in the mitochondrial genome.
    View
  • Brown Rudnick Llp
    Biotechnology Consultant
    Brown Rudnick Llp Jan 2024 - Present
    New York, Ny, Us
    BR BioAdvisory works seamlessly with the Brown Rudnick Global Life Sciences Legal team to provide integrated business and legal services to the biotech and pharma sectors. The BR BioAdvisory team leads client business initiatives, supported by Brown Rudnick’s lawyers, and provide additional technical and finance specialists to support client legal needs.
    View
  • Abvance Therapeutics
    Senior Advisor
    Abvance Therapeutics Sep 2022 - Present
    Abvance is a biotechnology company developing a new insulin: glucagon formulation called ABV100 for preventing hypoglycemia. Patients who use ABV100 instead of insulin will experience improved blood glucose control with a safety buffer against hypoglycemia. In addition, ABV100 does not require new behavioral changes or devices and will lighten the daily burden of disease management.
    View
  • Matrix Bio
    Senior Advisor
    Matrix Bio Jun 2023 - Present
    View
  • Artan Bio
    Chief Executive Officer
    Artan Bio Aug 2023 - Present
    Develops tRNA therapeutics for aging diseases.
    View
  • Hibiscus Bioventures
    Senior Advisor (Eir)
    Hibiscus Bioventures Sep 2021 - Present
    Rockville, Maryland, Us
    Building patient-focused companies around transformative biotechnologies.
    View
  • Biovisors
    Principal
    Biovisors Dec 2017 - Present
    BioVisors is a global life sciences strategic consulting firm. We provide our clients with competitive clinical, scientific and business services based from decades of experience in the biotechnology industry. Our team members have all held former executive positions at various pharmaceutical and medical device companies. We have first hand experience bringing technology from the bench to commercialization.
    View
  • Johns Hopkins University
    Professor
    Johns Hopkins University May 2016 - Present
    Baltimore, Md, Us
    • Developed and administered educational and research programs for an MBA focused on the startup of biotechnology companies.• Program classwork included venture capital/grant funding, regulatory requirements (FDA & EMA), scientific & clinical trial design, intellectual property and private versus public entities.
    View
  • Glg (Gerson Lehrman Group)
    Council Member - Consultant
    Glg (Gerson Lehrman Group) Apr 2016 - Present
    New York, Ny, Us
    • Advised biotechnology companies on strategy, operations and clinical development of drugs and diagnostics.• Educated internal groups on FDA regulatory processes and biotech investment strategy.
    View
  • Nucleate
    Mentor
    Nucleate Jan 2022 - Present
    Boston, Us
    Nucleate is a free and collaborative student-led organization that facilitates the formation of pioneering life sciences companies.
    View
  • Mayflower Bioventures
    Entrepreneur In Residence
    Mayflower Bioventures Oct 2022 - Apr 2023
  • Morphiex Biotherapeutics
    Chief Executive Officer & Co-Founder
    Morphiex Biotherapeutics Jan 2018 - Jan 2022
    Boston, Massachusetts, Us
    Morphiex is a biotechnology company harnessing the power of the immune system to fight cancer by developing the only dual-functioning #CD47 immune checkpoint inhibitor. Our lead drug candidate, MBT-001, blocks both "don't eat me" and thrombospondin-1 (TSP-1) pathways of #CD47. This enables direct tumor cell killing mediated by T cells, Natural Killer cells, Neutrophils as well as Macrophages.
    View
  • Deloitte
    Advisor & Subject Matter Expert - Life Sciences
    Deloitte Jan 2019 - Jan 2020
    Worldwide, Oo
    View
  • National Cancer Institute (Nci)
    Research Scientist
    National Cancer Institute (Nci) 2013 - Dec 2017
    Bethesda, Md, Us
    • Led a team to develop novel immunotherapy drugs and high throughput screening assays for cancer including small molecules, peptides, antibodies, RNAi and morpholinos• Directed a drug development program with Celgene for cancer to support human trials• Expert in phosphorodiamidate morpholino oligomer (PMO) pre-clinical/clinical development• Published in leading journals, books and international conferences• Considered a Key Opinion Leader in CD47 drug development and clinical trials• Filed US and European patents for immunotherapies for out-licensing• Aided in the formation of a startup biotechnology company based on technology developed at the NIH/NCI
    View
  • Athencion Biotech
    Co-Founder
    Athencion Biotech May 2015 - Nov 2017
    An early stage biotechnology company aimed at commercializing intellectual property developed by its founders for the treatment of cancer, diabetes and Alzheimer’s disease. The company’s lead drug candidate is in a late stage clinical trial for the treatment of sepsis in the veterinary market. • Obtained orphan drug designation for its lead asset in sepsis/endotoxemia• Established IND with US FDA for sepsis/endotoxeima• Designed and managed an ongoing clinical trial for the treatment of sepsis/endotoxemia• Pursued FDA conditional/full regulatory approval through INAD filings• Reviewed Quality Control of cGMP drugs• Applied for and received several grants to run clinical trials• Worked with the CFO to manage accounting and budgetswww.athencion.com
  • Phylomics, Llc
    Consultant
    Phylomics, Llc Jan 2015 - Jul 2017
    Provides early detection of cancer in presumably healthy individuals by analyzing blood serum.
  • Zacks Investment Research
    Biotechnology Buy-Side Consultant/Analyst
    Zacks Investment Research Jan 2014 - Jan 2015
    Chicago, Il, Us
    • Led an analytical team to conduct significant due diligence on small to large biotechnology companies which included clinical trial data analysis (Phase I-III), regulatory filings and FDA interactions, FDA advisory committee meetings (ADCOM) and NDA submissions.• Published full initiation reports of drug technology, clinical trials, valuations, financial models and recommendations featured on Bloomberg, The Markets, Wall Street Source, Reuters and Thomson-One.
    View
  • Interthyr Corporation
    President
    Interthyr Corporation Jan 2005 - Jun 2013
    Interthyr developed diagnostics and therapeutics for endocrine diseases, autoimmune-inflammatory diseases and cancer.• FDA approved diagnostic for Graves’ disease resulting in significant profits • Initiated and conducted a clinical trail for the treatment of endotoxemia/sepsis• Experienced with FDA negotiations for clinical trials in animals and humans• Extensive project management experience• Dealt with various legal situations including licensing agreements and royalty litigation• Responsible for all day to day activities including employee management and finances• Directed laboratory activities across three countries (US, South America, and Italy)• Actively negotiated with venture capitalists and angel investors• Inventor and patent holder on a class of methimazole derivatives for the treatment of autoimmune diseases and cancer• Executed IND-enabling experiments including rat, dog and primate studies• Developed a diagnostic assay for the detection of Wnt5a (a tumor biomarker)• Responsible in obtaining more than 5 million dollars in funding• Developed a drug eluting stent for atherosclerosis• Extensive experience in grant (STTR/SBIR) writing, patent submission, and patent law• Author of several peer-reviewed cancer and autoimmune disease related articles• Presenter and invited speaker at multiple national and international meetings
    View
  • Xtell Corp
    President, Founder
    Xtell Corp Jan 2001 - Apr 2012
    Specialized in the development of an artificial intelligence based electronic medical records software, high-speed data services and biospecimen storage & processing. • Developed a leading artificial intelligence based electronic health records (EHR) software package• Provided high speed data services and connectivity throughout multiple hospital systems across several states• Designed the first human biorepository for autoimmune & endocrine diseases that stored RNA, DNA, protein and patient blood samples directly linked to patient medical records• Software developed allowed physicians and researchers to mine patient data with clinical samples to support drug development and clinical trial programs• Managed customers, employees, vendors and budgets• The Company’s client base was acquired in 2012
  • Colorado State University
    Graduate Research Associate
    Colorado State University Aug 2009 - Jan 2012
    Fort Collins, Co, Us
    Evaluated the ability of bone marrow derived mesenchymal stems cells to regenerate bone post-Stereotactic Radiotherapy of osteosarcoma (Dissertation topic). Also initiated an ongoing clinical trial with a novel TLR inhibitor for the treatment of sepsis.
    View
  • University G D’Annunzio
    Research Associate
    University G D’Annunzio Jan 2009 - Jan 2010
    Conducted pre-clinical drug studies focused on targeting the inflammatory TLR signaling pathways and Plasminogen activator inhibitor-1 (PIA-1) in a Type 1 Diabetic rat model.
  • Ohio University
    Graduate Research Associate
    Ohio University Sep 2007 - Jan 2009
    Athens, Ohio, Us
    Developed anti-tumor small molecule inhibitors of TLR in multiple human pancreatic cancer cells lines in vitro and in vivo. Conducted more than 20 pre-clinical tumor implanted animal studies and evaluated growth inhibition of several TLR inhibiting drugs (Thesis Topic).
    View
  • American Cancer Society
    Co-Founder American Cancer Society Teens
    American Cancer Society Jan 2000 - Jan 2003
    Atlanta, Ga, Us
    Co-Founder of the national youth volunteer involvement task force of the American Cancer Society that is now present in 50 states.
    View

Anthony Schwartz Skills

Stem Cells Financial Advisory Litigation Clinical Trials Consulting Endocrine Cell Biology Books In Vivo Community Hardware Diagnostics Undergraduate Prostate Infectious Diseases Students Clinical Research Investment Research Biotechnology Veterinary Immunology Mentoring Minded Finance Ehr Thyroid U.s. Food And Drug Administration Adme Medical Records Idea Generation Specimen Collection Symposium Nda Rna Clinical Development Legal Reuters Scholarships Treatment Detection Disease Cancer Travel Management Research Funding Peptides Computer Science Science Childhood Funding Cycling Journals Patents Toxicology Protein Chemistry Bioengineering Featured Initiation Regulatory Projects Publications Source Accounting Blood Hplc Cros Valuation Gmp Patent Prosecution Press Releases Breast Antibodies Physicians Volunteering Licensing Agreements Cell Bloomberg Pcr Education Validation Fundraising Us Equities Reports Kayak Drug Testing Sepsis Radiation Therapy Connecting Artificial Intelligence Lifesciences Funders Rowing Oncology Drug Development Patient Institutes Diabetes Conferences Melanoma Project Management Product Development American Research Quality Control International Conferences Venture Capital Capital Radiation Ema R&d Through Design Microscopy Biopharmaceuticals Combination Hospitals Highly Ambitious Endurance R Trials Sports C Space Corporate Venture Capital Query Writing Regulatory Filings Biomedical Engineering Data Analysis Assay Development Royalties Data Collection Business Development Negotiation Dna Life Sciences Cell Culture Advertising Scientific Safety Characterization Regulatory Requirements Stage Suite Miller Drug Discovery Molecular Biology Out Licensing Ohio Colorado Marketing Big Data High Throughput Electrical Engineering Timelines Mining Pipelines Pharmacology Data Driven Testing Breast Cancer Genetics Biochemistry Intellectual Property Rnai Technology Transfer Corporate Development Data Migration Ultra Nature Therapists Cancer Research Pathway Regulations High Throughput Screening Intelligence Small Molecules Elisa Educational Programs Genomics Start Ups Prototype Connectivity Diagnostics Medical Devices Software Equities Wink Critical Care Medicine Wall Street Resistance Viability Bioinformatics Pharmaceutics Pancreatic In Vitro Stability Italy Endocrinology Budgets Colon Scientists Due Diligence High Speed Data Pharmaceutical Industry Trading Filing Conceptual Modeling Meetings Greece Immunotherapy Mergers And Acquisitions Fda Evaluation Commercialization Selling Signalling

Anthony Schwartz Education Details

  • Colorado State University
    Colorado State University
    Biomedical Engineering
  • Colorado State University
    Colorado State University
    Business Administration
  • Ohio University
    Ohio University
    Biomedical Engineering
  • Ohio University
    Ohio University
    Electrical Engineering & Computer Science

Frequently Asked Questions about Anthony Schwartz

What company does Anthony Schwartz work for?

Anthony Schwartz works for Miletus Biotechnology

What is Anthony Schwartz's role at the current company?

Anthony Schwartz's current role is Chief Operating Officer.

What is Anthony Schwartz's email address?

Anthony Schwartz's email address is an****@****ail.com

What is Anthony Schwartz's direct phone number?

Anthony Schwartz's direct phone number is +151265*****

What schools did Anthony Schwartz attend?

Anthony Schwartz attended Colorado State University, Colorado State University, Ohio University, Ohio University.

What are some of Anthony Schwartz's interests?

Anthony Schwartz has interest in 24 Hour Bike Race, Drug And Diagnostic Development, Mountain/road Biking, Greece, Ultra Endurance Events, Triathlons, Professional Equity Trader, Extreme Sports, Travel.

What skills is Anthony Schwartz known for?

Anthony Schwartz has skills like Stem Cells, Financial Advisory, Litigation, Clinical Trials, Consulting, Endocrine, Cell Biology, Books, In Vivo, Community, Hardware Diagnostics, Undergraduate.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.